OR WAIT null SECS
February 22, 2021
With the acquisition, Eurofins gets Beacon’s G-protein coupled receptor research knowledge and its compound library.
Once the vaccine has been authorized, Sanofi will provide Johnson & Johnson with access to its vaccine manufacturing plant in Marcy l’Etoile, France, to formulate and fill vials of the vaccine, at a rate of 12 million doses per month.
The second phase of the Myford facility expansion in California will add upstream and downstream processing suites.
February 18, 2021
The company has completed the expansion of its laboratory facilities to accommodate the development of APIs.
The deal expands Wavelength’s drug substance manufacturing footprint and its API CDMO business.
Through the agreement, Catalent will manufacture LUPKYNIS (voclosporin), Aurinia’s drug for the treatment of adult patients with lupus nephritis, at its pharmaceutical softgel center of excellence in St. Petersburg, FL.
The companies have expanded their agreement to include the research and development of new therapies for influenza and other respiratory viruses.
Cascade began production on new facilities to manufacture APIs for clinical and commercial GMP production.
February 17, 2021
The companies have expanded their existing partnership to include 40 Million Doses of COVID-19 vaccine for South Korea.
The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.